TriLink BioTechnologies, a subsidiary of Maravai, that provides gene therapy services to researchers, has announced it will relocate to expand the company’s operations.
As Nordic Life Science Days draws to a close for 2018, so too do the conference ‘super sessions’, covering patient engagement, precision medicine, drug delivery and immune-oncology.
Biopharma-Reporter is on the ground, bringing you the...
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.
Novartis is working with the US FDA to solve a manufacturing issue affecting Kymriah, identified as ‘variability in its commercial specifications’, says CEO.
PTC Therapeutics will acquire Agilis Biotherapeutics to continue work on gene therapy for rare monogenic diseases affecting the central nervous system.
The US FDA has released draft guidance documents on gene therapy programmes, which “should help sponsors avoid expending time and resources on unproductive drug development efforts,” says expert.
Pluristem Therapeutics has announced that it has agreed a strategic collaboration with Thermo Fisher to improve the process by which cell therapies are manufactured.
Infusing CAR T-cells directly into the brain, rather than into the blood intravenously, could improve the immunotherapy’s effectiveness and produce fewer side effects, say researchers.
Plasticell, alongside Great Ormond Street Hospital and the UCL Institute of Child Health, have announced they will collaborate to develop technology to better develop and manufacture gene therapies.
Cellectis has built a switch into a chimeric antigen receptor (CAR) T-cell to provide an efficient way to eliminate the therapy if it becomes a threat to patient safety.
